Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus TEXACORT.
FLOVENT DISKUS 50 vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid